

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/050655 A1

(51) International Patent Classification⁷: **C07D 417/12, A61K 31/428, A61P 25/18**

7-1-27 Ameerpet, Hyderabad, 500 016 Andhra Pradesh (IN).

(21) International Application Number:
PCT/US2003/038489

(74) Agents: JANET, I., Cord et al.; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US).

(22) International Filing Date: 4 December 2003 (04.12.2003)

(81) Designated States (national): AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (BW, GU, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NH, SN, TD, TG).

(26) Publication Language: English

Published:

(30) Priority Data:
907/MAS/2002 4 December 2002 (04.12.2002) IN

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicants (for all designated States except US): DR. REDDY'S LABORATORIES LIMITED [IN/IN]; 7-1-27, Ameerpet, Hyderabad, 500 016 Andhra Pradesh (IN). DR. REDDY'S LABORATORIES INC. [US/US]; One Park Way, Upper Saddle River, NJ 07458 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/050655 A1

(54) Title: POLYMORPHIC FORMS OF ZIPRASIDONE AND ITS HYDROCHLORIDE

(57) Abstract: The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and commercially suitable.

- 1 -

POLYMORPHIC FORMS OF ZIPRASIDONE AND ITS HYDROCHLORIDE

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority of Indian Patent Application No. 5 907/MAS/2002, filed December 4, 2002, the disclosure of which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to new amorphous form of ziprasidone hydrochloride and crystalline forms of ziprasidone and its hydrochloride salt, processes 10 for preparation thereof, and compositions containing the amorphous and crystalline forms.

The present invention also relates to a method of treating a psychosis, comprising administering to a patient in need of such treatment an effective amount of amorphous form of ziprasidone hydrochloride or crystalline forms of ziprasidone or its hydrochloride salt

BACKGROUND OF THE INVENTION

Ziprasidone, 5-(2-(4-(1,2-benzisothiazole-3yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indole-2-one is an anti psychotic agent that is used for the treatment of psychotic disorders of the schizophrenic types, and is also useful for removing or ameliorating such symptoms as anxiety, agitation, excessive aggression, 20 tension and social or emotional withdrawal in psychotic patients.

It is known that polymorphic forms of the same drug may have substantial differences in certain pharmaceutically important properties. Therefore, there is a continuing need for new solid forms of ziprasidone and its salts and new methods of preparation.

SUMMARY OF THE INVENTION

The invention relates to an amorphous form of ziprasidone hydrochloride. Preferably, the amorphous form of ziprasidone hydrochloride may have substantially the same X-ray diffraction pattern as shown in Figure 1. Various embodiments and variants are provided.

The invention also relates to a composition that comprises ziprasidone hydrochloride in a solid form, wherein at least 80 % by weight of the solid ziprasidone hydrochloride is an amorphous form of ziprasidone hydrochloride.

The invention also relates to a process for preparation of amorphous form of ziprasidone hydrochloride by converting ziprasidone to amorphous ziprasidone hydrochloride.

- 2 -

The invention also relates to a pharmaceutical composition that comprises an amorphous form of ziprasidone hydrochloride and one or more pharmaceutically acceptable carriers or diluents. Preferably, the pharmaceutical composition is in a solid dosage form for oral administration, such as a tablet.

5 The invention also relates to a crystalline form of ziprasidone. Preferably, the crystalline form of ziprasidone has an X-ray diffraction pattern, expressed in terms of 2 theta angles, that includes four or more peaks selected from the group consisting of 16.34 ± 0.009 , 12.21 ± 0.009 , 25.16 ± 0.009 , 27.02 ± 0.009 , 24.21 ± 0.009 , 5.26 ± 0.009 and 18.51 ± 0.009 degrees. The invention also relates to a pharmaceutical composition having the crystalline form of ziprasidone. Pharmaceutical compositions of the invention may be formulated, for example, as solid dosage forms for oral administration.

10 The invention also relates to a method of treating a psychosis, comprising administering to a patient in need of such treatment an effective amount of an amorphous form of ziprasidone hydrochloride or crystalline forms of ziprasidone or its hydrochloride salt.

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS

Figure 1 shows a sample X-ray power diffractogram of an amorphous form of ziprasidone hydrochloride.

20 Figure 2 shows a sample X-ray power diffractogram of a crystalline form of ziprasidone.

DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.

25 Unless stated to the contrary, any use of the words such as "including," "containing," "comprising," "having" and the like, means "including without limitation" and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. Embodiments of the invention are not mutually exclusive, but may be implemented in various combinations. The described embodiments of the invention and the disclosed examples are given for the purpose of illustration rather than limitation of the invention as set forth the appended claims.

30 For purposes of the present invention, the following terms are defined below.

- 3 -

"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and includes that which is acceptable for veterinary use and/or human pharmaceutical use.

5 The term "composition" includes, but is not limited to, a powder, a suspension, an emulsion and/or mixtures thereof. The term composition is intended to encompass a product containing the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. A "composition" may contain a single compound or a mixture of compounds.

10 The term "pharmaceutical composition" is intended to encompass a product comprising the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or
15 interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing the active ingredient, additional active ingredient(s), and pharmaceutically acceptable excipients.


20 The term "excipient" means a component of a pharmaceutical product that is not the active ingredient, such as filler, diluent, carrier, and so on. The excipients that are useful in preparing a pharmaceutical composition are preferably generally safe, non-toxic and neither biologically nor otherwise undesirable, and are acceptable for veterinary use as well as human pharmaceutical use. "A pharmaceutically acceptable excipient" as used in the specification and claims includes both one and more than one such excipient.

25 When referring to a chemical reaction, the terms "treating", "contacting" and "reacting" are used interchangeably herein and refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction, which produces the indicated and/or the desired product, may not necessarily result directly from the combination of two reagents, which were initially added, *i.e.*, there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product. Also, the term "isolating" is used to indicate separation of the compound being isolated regardless of the purity of the isolated compound from any unwanted substance which presents with the compound as a mixture. Thus, degree of the purity of the isolated or separated compound does not affect the status of "isolating".
30
35

- 4 -

The term "substantially free of" in reference to a composition, as used herein, means that said substance cannot be detected in the composition by methods known to those skilled in the art at the time of the filing of this application.

Ziprasidone hydrochloride has the chemical structure,



5

U.S. Patent 5,312,925 discloses mono and hemi hydrated forms and anhydrous form of ziprasidone hydrochloride, which are characterized by X-ray diffractograms and Infrared spectra. The ziprasidone hydrochloride monohydrate crystal form was prepared by treating ziprasidone with aqueous hydrochloric acid at an elevated temperature, followed by controlled drying. For convenience, the crystalline form of ziprasidone hydrochloride monohydrate disclosed in U.S. Patent 5,312,925, herein incorporated by reference, is designated as crystalline Form I.

Different solid forms of the same drug may exhibit different properties, including characteristics that have functional implications with respect to their use as active ingredients of pharmaceutical products. For example, polymorphs of the same drug may have substantial differences in such pharmaceutically important properties as dissolution rates and bioavailability. Likewise, different polymorphs may have different processing properties, such as hydroscopicity, flowability, and the like, which could affect their suitability as active pharmaceuticals for commercial production.

Crystalline ziprasidone hydrochloride may be preferably prepared by making a suspension of ziprasidone in a ketone solvent, such as acetone, diethyl ketone, methyl isobutyl ketone, methyl ethyl ketone or mixtures thereof. Then aqueous hydrochloric acid solution is added to the suspension, and the resulting mixture is heated to an elevated temperature, preferably reflux temperature. The reaction mixture may be heated for 1-24 hours but preferably for 1-2 hours. After the heating, the reaction mixture is cooled preferably to ambient temperature. A solid is formed and may be isolated by any conventional filtering technique. The isolated solid may then be dried at an elevated temperature, preferably between about 50°C and about 100°C until a constant weight of the solid is obtained to afford crystalline ziprasidone hydrochloride. The moisture content of crystalline ziprasidone hydrochloride obtained may be between about 3.5 and about

- 5 -

4.5 % by weight. The moisture content of the present invention may be measured on Mettler DL-35 instrument using Karl-Fisher reagent.

It is readily understood by one of ordinary skill in the art that the reaction times set forth above may vary depending upon the amount of the reactants used in the process.

Ziprasidone used in the process of the invention may be crude or purified and may be crystalline or amorphous. The ziprasidone itself may be obtained via a condensation of 5-(2-chloroethyl)-6-chloro oxindole and 3-(1-piperazinyl)-1,2-benzisothiazole or via the synthesis described in U.S. Patent No. 5,338,846, which is herein incorporated by reference or by titrating an acid addition salt of ziprasidone with a base such as, for example, sodium hydroxide or potassium hydroxide.

The invention relates to an amorphous form of ziprasidone hydrochloride. The amorphous form of ziprasidone hydrochloride of the invention can have a moisture content preferably between about 0.5 and about 7.5 %, more preferably between about 0.5 and about 4.5 % by weight, even more preferably between about 3.5 and about 4.5 %, yet further preferably between about 4.0 and about 4.5 %.

A particular process for preparation of an amorphous form of ziprasidone hydrochloride is provided and includes: a) providing ziprasidone hydrochloride solution in an aqueous alcoholic solvent; b) removing said solvent, thereby forming a solid mass; and d) isolating said solid mass, which is the amorphous form of ziprasidone hydrochloride. The aqueous alcoholic solvent is a mixture of water and a lower alky alcohol such as an alcoholic solvent such as ethanol, methanol, propanol, t-butanol, n-butanol, isopropanol or mixtures thereof. The solution of ziprasidone hydrochloride may be prepared by directly dissolving solid ziprasidone hydrochloride in an alcoholic solvent or may be prepared by using ziprasidone which is then treated by hydrochloric acid. A particular process for the preparation of ziprasidone hydrochloride solution used in this aspect of the invention may include: a) suspending ziprasidone base in acetic acid; b) adding aqueous hydrochloric acid solution at slightly above the ambient temperature, preferably at about 30-70°C, preferably 40-50°C; c) adding water and an alcoholic solvent such as ethanol, methanol, propanol, t-butanol, n-butanol, isopropanol or mixtures thereof; and d) heating the reaction mixture to an elevated temperature for 1-24 hours, preferably 1-2 hours.

The elevated temperature may be any temperature that allows a clear solution of the reaction mixture but preferably is reflux temperature.

- 6 -

5 The removal of the solvent may be done under reduced pressure and the obtained solid cake is then isolated by a conventional technique, which may or may not include washing the solid cake with a fresh cold water or an aqueous alcoholic solvent such as a mixture of water and a lower alkyl alcohol, e.g. ethanol, methanol, propanol, t-butanol, n-butanol, isopropanol or mixtures thereof. The obtained amorphous form of ziprasidone may be dried at an elevated temperature, preferably at about 50°C – about 100°C.

10 The amorphous form of ziprasidone hydrochloride produced by this process may be characterized by an X-ray powder diffraction pattern, as for example shown in Figure 1. The X-ray diffractograms was measured on Bruker Axe, DS advance Power X-ray Diffractometer with Cu K alpha-1 Radiation source.

15 The invention also relates to a crystalline form of ziprasidone. The crystalline form of ziprasidone is prepared by a process comprising a) providing a solution of a salt of ziprasidone in an aqueous solvent; b) treating said solution with aqueous basic solution or caustic lye thereby forming a precipitate; and c) isolating the precipitate, which is the crystalline form of ziprasidone.

20 As a preferred embodiment, the solution of a salt of ziprasidone of the above process may be prepared by a) treating crude or purified ziprasidone with methane sulfonic acid in methanol media where the ziprasidone forms a mesylate salt; and b) dissolving the ziprasidone mesylate salt in water or in a mixture of water and an alcoholic solvent.

25 The aqueous basic solution is preferably a solution of alkali metal hydroxide in water such as, for example, sodium hydroxide or potassium hydroxide solution.

30 An X-ray powder diffraction pattern of the crystalline form of ziprasidone produced via the above process of the invention was obtained as shown in Figure 2, and the characteristic 2-theta values (in degrees) of the identified peaks in the X-ray diffractogram are 16.335, 12.209, 25.156, 27.019, 24.21, 5.2555 and 18.511. The X-ray diffractograms was measured on Bruker Axe, DS advance Power X-ray Diffractometer with Cu K alpha-1 Radiation source.

35 It should be kept in mind that slight variations in observed 2 theta angles values are expected based on the specific diffractometer employed, the analyst and the sample preparation technique. More variation is expected for the relative peak intensities. Identification of the exact crystalline form of a compound should be based primarily on observed 2 theta angles with lesser importance attributed to relative peak intensities. The

- 7 -

peaks reported herein are listed in order of their peak intensities. Thus, the first listed peak has stronger intensity than the second listed peak in the pattern. 2 theta diffraction angles and corresponding d-spacing values account for positions of various peaks in the X-ray powder diffraction pattern. D-spacing values are calculated with observed 2 theta angles and copper K(α 1) wavelength using the Bragg equation well known to those of skill in the art.

Thus, some margin of error may be present in each of the 2 theta angle assignments reported herein. The assigned margin of error in the 2 theta angles for the crystalline form of ziprasidone is approximately ± 0.009 for each of the peak assignments. In view of the assigned margin of error, in a preferred variant, the crystalline form of ziprasidone may be characterized by an X-ray diffraction pattern, expressed in terms of 2 theta angles, that includes four or more peaks selected from the group consisting of 16.34 ± 0.009 , 12.21 ± 0.009 , 25.16 ± 0.009 , 27.02 ± 0.009 , 24.21 ± 0.009 , 5.26 ± 0.009 and 18.51 ± 0.009 degrees.

Since some margin of error is possible in the assignment of 2 theta angles and d-spacings, the preferred method of comparing X-ray powder diffraction patterns in order to identify a particular crystalline form is to overlay the X-ray powder diffraction pattern of the unknown form over the X-ray powder diffraction pattern of a known form. For example, one skilled in the art can overlay an X-ray powder diffraction pattern of an unidentified crystalline form of ziprasidone obtained using the methods described herein, over FIG. 2 and readily determine whether the X-ray diffraction pattern of the unidentified form is substantially the same as the X-ray powder diffraction pattern of the crystalline form of this invention. If the X-ray powder diffraction pattern is substantially the same as FIG. 2, the previously unknown crystalline form of ziprasidone can be readily and accurately identified as the crystalline form of this invention.

The invention also relates to a composition containing solid ziprasidone hydrochloride or solid ziprasidone, of which at least 80%, by total weight of the solid ziprasidone or its hydrochloride salt in the composition, is the corresponding crystalline form or an amorphous form. The invention also relates to the composition of solid ziprasidone hydrochloride comprising at least 80%, by total weight, the amorphous form of ziprasidone hydrochloride. In the more preferred form of this composition, the solid ziprasidone hydrochloride is suitable for use as active ingredient in formulating pharmaceutical products. The remainder of the solid ziprasidone hydrochloride in the composition, i.e., 20% or less of the total weight of ziprasidone hydrochloride, may be crystalline Form I of ziprasidone hydrochloride. In an embodiment of the invention, the

- 8 -

composition may comprise at least 90% of the amorphous form of ziprasidone hydrochloride with respect to total weight of the solid ziprasidone hydrochloride in the composition. In another embodiment of the invention, the composition may comprise at least 95% of the amorphous form of ziprasidone hydrochloride with respect to total weight of the solid ziprasidone hydrochloride in the composition. In yet another embodiment of the invention, the composition is substantially free of any forms of ziprasidone hydrochloride other than its amorphous form.

The invention also relates to a composition of solid ziprasidone comprising at least 80%, by total weight of the crystalline of ziprasidone, which is set forth in this specification. The solid ziprasidone is suitable for use as active ingredient in formulating pharmaceutical products. In an embodiment of the invention, the composition may comprise at least 90% of the crystalline form of ziprasidone with respect to total weight of the solid ziprasidone in the composition. In another embodiment of the invention, the composition may comprise at least 95% of the crystalline form of ziprasidone with respect to total weight of the solid ziprasidone in the composition. In yet another embodiment of the invention, the composition is substantially free of any forms of ziprasidone other than its crystalline form.

X-ray diffraction provides a convenient and practical means for quantitative determination of the relative amounts of crystalline and/or amorphous forms in a solid mixture. X-ray diffraction is adaptable to quantitative applications because the intensities of the diffraction peaks of a given compound in a mixture are proportional to the fraction of the corresponding powder in the mixture. The percent composition of crystalline ziprasidone or its hydrochloride salt in an unknown composition can be determined. Preferably, the measurements are made on solid powder ziprasidone or its hydrochloride salt. The X-ray powder diffraction patterns of an unknown composition can be compared to known quantitative standards containing pure crystalline forms of ziprasidone or its hydrochloride salt to identify the percent ratio of a particular crystalline form. This is done by comparing the relative intensities of the peaks from the diffraction pattern of the unknown solid powder composition with a calibration curve derived from the X-ray diffraction patterns of pure known samples. The curve can be calibrated based on the X-ray powder diffraction pattern for the strongest peak from a pure sample of crystalline forms of ziprasidone or its hydrochloride salt. The calibration curve may be created in a manner known to those of skill in the art. For example, five or more artificial mixtures of crystalline forms of ziprasidone or its hydrochloride salt, at different amounts, may be prepared. In a non-limiting example, such mixtures may contain, 2%, 5%, 7%,

- 9 -

8%, and 10% of ziprasidone or its hydrochloride salt for each crystalline form. Then, X-ray diffraction patterns are obtained for each artificial mixture using standard X-ray diffraction techniques. Slight variations in peak positions, if any, may be accounted for by adjusting the location of the peak to be measured. The intensities of the selected characteristic peak(s) for each of the artificial mixtures are then plotted against the known weight percentages of the crystalline form. The resulting plot is a calibration curve that allows determination of the amount of the crystalline forms of ziprasidone or its hydrochloride salt in an unknown sample. For the unknown mixture of crystalline and amorphous forms of ziprasidone or its hydrochloride salt, the intensities of the selected characteristic peak(s) in the mixture, relative to an intensity of this peak in a calibration mixture, may be used to determine the percentage of the given crystalline form in the composition, with the remainder determined to be the amorphous material.

Pharmaceutical compositions comprising amorphous form of ziprasidone hydrochloride or the crystalline form of ziprasidone can be formulated with a one or more pharmaceutically acceptable carriers, also known as excipients, which ordinarily lack pharmaceutical activity, but have various useful properties which may, for example, enhance the stability, sterility, bioavailability, and ease of formulation of a pharmaceutical composition. These carriers are pharmaceutically acceptable, meaning that they are not harmful to humans or animals when taken appropriately and are compatible with the other ingredients in a given formulation. The carriers may be solid, semi-solid, or liquid, and may be formulated with the compound in bulk. The resulting mixture may be manufactured in the form of a unit-dose formulation (i.e., a physically discrete unit containing a specific amount of active ingredient) such as a tablet or capsule. The pharmaceutical compositions may include, in addition to a compound of this invention, one or more active pharmaceutical compounds.

Generally, the pharmaceutical compositions of the invention may be prepared by uniformly admixing the active ingredient with liquid or solid carriers and then shaping the product into the desired form. The pharmaceutical compositions may be in the form of suspensions, solutions, elixirs, aerosols, or solid dosage forms. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed.

A preferred oral solid preparation is a tablet. A tablet may be prepared by direct compression, wet granulation, or molding, of the active ingredient(s) with a carrier and other excipients in a manner known to those skilled in the art. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-

- 10 -

flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active agent or dispersing agent. Molded tablets may be made on a suitable machine. A mixture of the powdered compound moistened with an inert liquid diluent is suitable in the case of oral solid dosage forms (e.g., powders, capsules, and tablets). If desired, tablets may be coated by standard techniques. The compounds of this invention may be formulated into typical disintegrating tablets, or into controlled or extended release dosage forms. Examples of suitable controlled release formulation vehicles are disclosed in U.S. Patents Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, incorporated herein by reference in their entireties.

The pharmaceutical compositions of the invention are contemplated in various formulations suitable for various modes of administration, including but not limited to inhalation, oral, rectal, parenteral (including subcutaneous, intradermal, intramuscular, intravenous), implantable, intravaginal and transdermal administration. The most suitable route of administration in any given case depends on the duration of the subject's condition, the length of treatment desired, the nature and severity of the condition being treated, and the particular formulation that is being used. The formulations may be in bulk or in unit dosage form.

The amount of active ingredient included in a unit dosage form depends on the type of formulation that is formulated. A pharmaceutical composition of the invention will generally comprise about 0.1% by weight to about 99% by weight of active ingredient, preferably about 1% by weight to 50% by weight for oral administration and about 0.2% by weight to about 20% by weight for parenteral administration.

Formulations suitable for oral administration include capsules (hard and soft), cachets, lozenges, syrups, suppositories, and tablets, each containing a pre-determined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy that includes the step of bringing into association the active compound and a suitable carrier or carriers. The amount of active ingredient per unit dosage of solid formulations may be as described in prior art for preparations of ziprasidone and its hydrochloride salt. For liquid oral formulations, a preferable amount is from about 2% by weight to about 20% by weight. Suitable carriers include but are not limited to fillers, binders, lubricants, inert diluents, surface active/dispersing agents, flavorants, antioxidants, bulking and granulating agents, adsorbents, preservatives, emulsifiers, suspending and wetting agents, glidants, disintegrants, buffers and pH-adjusting agents, and colorants. Examples of

- 11 -

carriers include celluloses, modified celluloses, cyclodextrins, starches, oils, polyols, sugar alcohols and sugars, and others. For liquid formulations sugar, sugar alcohols, ethanol, water, glycerol, and polyalkylene glycols are particularly suitable, and may also be used in solid formulations. Cyclodextrins may be particularly useful for increasing 5 bioavailability. Formulations for oral administration may optionally include enteric coatings known in the art to prevent degradation of the formulation in the stomach and provide release of the drug in the small intestine.

Formulations suitable for buccal or sub-lingual administration include 10 lozenges comprising the active compound in a flavored base, usually sucrose and acacia or tragacanth, although other agents are also suitable, and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations suitable for rectal administration are preferably presented as 15 unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, e.g., cocoa butter, and then shaping the resulting mixture.

In another aspect, the invention also provides methods of treating a psychosis, comprising administering to a patient in need of such treatment an effective amount of a composition comprising the amorphous form of ziprasidone hydrochloride or the crystalline form of ziprasidone and a pharmaceutically acceptable carrier. 20

The effective amount (i.e., dosage) of active compound for treatment will vary depending on the route of administration, the condition being treated, its severity, and duration, and the state and age of the subject. A skilled physician will monitor the progress of the subject and will adjust the dosage accordingly, depending on whether the goal is to eliminate, alleviate, or prevent a given condition. Generally, the dosage should 25 be considered in proportion to the subject's weight. The daily dose of particular formulations of active compound may be divided among one or several unit dose administrations. For example therapeutic administration about fifteen to thirty minutes before main meals is preferable (i.e. three times daily), although administration of the active compounds may be carried out prophylactically, and may be maintained for prolonged periods of time. One skilled in the art will take such factors into account when 30 determining dosage. Unit dosage of active ingredient may range from about 0.1 to about 2g or from about 0.1 to about 2g.

The invention is further described by reference to the following examples which set forth in detail the preparation of compounds and compositions of the present 35 invention, as well as their utility. It will be apparent to those skilled in the art, that many

- 12 -

modifications, both to materials, and methods, may be practiced without departing from the purpose and interest of this invention. The examples that follow are not intended to limit the scope of the invention as described hereinabove or as claimed below.

REFERENCE EXAMPLE 1

5

Preparation of 5-(2-Chloro ethyl) -6-chloro oxindole

10

Triethylsilane (57.2 gm) was added slowly to the reaction mixture of 5-(2-Chloro acetyl) -6-chloro oxindole (50.0 gm) and trifluoroacetic acid (175 mL) below the temperature of 45°C. The reaction was maintained at 40–45°C for 6 hours. The reaction mass was cooled to 0°C to –5°C and maintained stirring for 90 minutes. The separated solid was filtered and washed with water (50 mL). Then the wet compound was further slurried in water (250 mL) for 90 minutes. The resultant solid was filtered, washed with water (50 mL) and dried at a temperature of 70–75°C to afford 5-(2-chloroethyl) -6-chloro oxindole (43.5 gm).

REFERENCE EXAMPLE 2

15

Preparation of Ziprasidone base

20

Refluxed the reaction mixture of 5-(2-chloroethyl) -6-chloro oxindole (100 gm), 3-(1-piperazinyl)-1,2-benzisothiazole (104.7 gm), sodium carbonate (92.2 gm), sodium iodide (6.4 gm), tetra butyl ammonium bromide (28 gm) and cyclohexane (1000 mL) till the reaction was completed. The reaction mass was cooled to a temperature of 30°C and the solid was filtered. To the wet compound was added water (1000 mL) and continued stirring for 45 minutes. The solid was filtered and washed with water (100 mL). To the water wet compound was added acetone (500 mL) and there was stirring for 2 hours at room temperature. The compound was filtered and washed with acetone (200 mL) and dried at a temperature of 70–75°C to afford the Crude Ziprasidone base (156.9 g)

25

REFERENCE EXAMPLE 3

Preparation of Ziprasidone base

30

35

Charged 5-(2-chloroethyl) -6-chloro oxindole (50 gm), 3-(1-piperazinyl)-1,2-benzisothiazole (47.5 gm) and cyclohexane (500 mL) into an autoclave. To this sodium carbonate (46 gm), sodium iodide (3.2 gm), tetra butyl phosphonium bromide (14.8 gm) was added and the reaction was maintained at a temperature of 95–102°C and the pressure was kept at 2.5 kg/cm² till the reaction was completed. The reaction mass was cooled to 30°C and water (250 mL) was added. The resulting compound was filtered and washed with water (100 mL). The wet compound was further slurried in water (500 mL), filtered and washed with water (100 mL). To the water wet compound was added acetone (500 mL) and was stirred at room temperature for 2 hours and 30 minutes. The

- 13 -

solid was filtered, washed with acetone (100 mL) and dried at a temperature of 60-65°C to afford the Ziprasidone base (65.7 gm).

EXAMPLE 1

Preparation of amorphous form of Ziprasidone hydrochloride

5 Ziprasidone (5g) and 50 mL of acetic acid were placed into a round bottom flask and heated to 45 – 50°C. Added was 25 mL of aqueous hydrochloric acid slowly to the mixture over 20 min. Then the reaction mixture was refluxed. Water (10 mL) was added, followed by addition of 50 mL of Isopropanol. The reaction mass was cooled to 50°C and distilled off the solvent completely under vacuum. The material formed was
10 scratched from the flask.

EXAMPLE 2

Preparation of crystalline form of Ziprasidone

Sodium carbonate (56.3 g) and 500 mL of water were placed into a round bottom flask. Added was 50 g of 3-(1-piperazinyl)-1,2-benzisothiazole hydrochloride and
15 50 g of 6-Chloro-5-(2-Chloroethyl) oxindole. The reaction mixture was then refluxed for 15 hours. The reaction completion was monitored by TLC. The reaction mass was cooled to room temperature. The resulting compound was filtered and washed with 50 mL of water. The wet compound and 250 mL of acetone were placed into a flask and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was
20 filtered to give a solid cake, which was washed with 50 mL of acetone. The wet cake and 750 mL of methanol were placed into a flask, which was heated to 50°C, and 14 mL of methane sulfonic acid was added to the solution over 20 minutes. The resulting reaction mass was cooled to room temperature and was subjected to a filtration to give a solid compound, which was washed with methanol. The wet compound and 750 mL of water
25 were placed into a flask, and then pH of the solution was adjusted to pH 9 with caustic lye. The reaction mixture was then stirred at room temperature for 1 hour and filtered. The filtered compound was washed with water and dried at 70°C to give 65 g of crystalline form Ziprasidone base.

- 14 -

CLAIMS

1. A compound, which is an amorphous form of ziprasidone hydrochloride.
2. The compound of claim 1, having substantially the same X-ray diffraction pattern as shown in Figure 1.
- 5 3. The compound of claim 1, wherein said amorphous form of ziprasidone hydrochloride has a moisture content between about 0.5 and about 4.5 % by weight.
4. The compound of claim 1, wherein said amorphous form of ziprasidone hydrochloride has a moisture content between about 3.5 and about 4.5 % by weight.
5. The compound of claim 1, wherein said amorphous form of ziprasidone hydrochloride has a moisture content between about 4.0 and about 4.5 % by weight.
- 10 6. A composition comprising ziprasidone hydrochloride as a solid, wherein at least 80 % by weight of said solid ziprasidone hydrochloride is an amorphous form of ziprasidone hydrochloride.
- 15 7. The composition of claim 6, wherein at least 90 % by weight of said solid ziprasidone hydrochloride is the amorphous form.
8. The composition of claim 6, wherein at least 95 % by weight of said solid ziprasidone hydrochloride is the amorphous form.
9. The composition of claim 6, wherein at least 99 % by weight of said solid ziprasidone hydrochloride is the amorphous form.
- 20 10. The composition of claim 6, wherein said ziprasidone hydrochloride is substantially free of its crystalline Form I.
11. The composition of claim 6, wherein at least 1 % of said solid ziprasidone hydrochloride is not the crystalline Form I.
- 25 12. The composition of claim 6, wherein at least 5 % of said solid ziprasidone hydrochloride is not the crystalline Form I.
13. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients.
14. The pharmaceutical composition of claim 13, wherein said composition is a solid dosage form for oral administration.
- 30 15. The pharmaceutical composition of claim 13, wherein said dosage form is a tablet.
16. A method of treating a psychosis, comprising administering to a patient in need of such treatment an effective amount of the compound of claim 1.
17. A process for making ziprasidone hydrochloride, wherein said process comprising converting ziprasidone to ziprasidone hydrochloride.

- 15 -

18. A process for making an amorphous form of ziprasidone hydrochloride, wherein said process comprising converting ziprasidone to ziprasidone hydrochloride.
19. The process of claim 18, wherein said ziprasidone is a crystalline form, an amorphous form or a mixture thereof.
- 5 20. The process of claim 18, wherein said ziprasidone is a crystalline form.
21. The process of claim 18, wherein said ziprasidone is an amorphous form.
22. A process for making an amorphous form of ziprasidone hydrochloride, said process comprising:
 - a. providing a ziprasidone hydrochloride solution in an aqueous alcoholic solvent;
 - 10 b. removing said solvent, thereby forming a solid mass; and
 - c. isolating said solid mass, which is the amorphous form of ziprasidone hydrochloride.
23. The process of claim 22, wherein said aqueous alcoholic solvent is a mixture of water and an alcohol selected from the group consisting of ethanol, methanol, propanol, t-butanol, n-butanol, isopropanol, and mixtures thereof.
- 15 24. The process of claim 22, wherein said aqueous alcoholic solvent is a mixture of water and isopropyl alcohol.
25. The process of claim 22, wherein said ziprasidone hydrochloride solution is provided by a process comprising mixing ziprasidone in acetic acid with aqueous hydrochloric acid solution.
- 20 26. The process of claim 25, wherein said ziprasidone is a crystalline form, an amorphous form or a mixture thereof.
27. The process of claim 25, wherein said ziprasidone is a crystalline form.
- 25 28. The process of claim 25, wherein said ziprasidone is an amorphous form.
29. The process of claim 25, wherein said mixing is done at a temperature between about 30°C and about 70°C.
- 30 30. The process of claim 25, wherein said mixing is done at a temperature between about 40°C and about 50°C.
31. The process of claim 25, wherein said process for providing the ziprasidone hydrochloride solution further comprises heating to an elevated temperature.
32. The process of claim 25, wherein said process for providing the ziprasidone hydrochloride solution further comprises heating to reflux temperature.
33. An amorphous form of ziprasidone hydrochloride, which is prepared according to the process of claim 18.

- 16 -

34. An amorphous form of ziprasidone hydrochloride, which is prepared according to the process of claim 22.
35. A compound which is a crystalline form of ziprasidone having an X-ray diffraction pattern, expressed in terms of 2 theta angles, that includes four or more peaks selected from the group consisting of 16.34 ± 0.009 , 12.21 ± 0.009 , 25.16 ± 0.009 , 27.02 ± 0.009 , 24.21 ± 0.009 , 5.26 ± 0.009 and 18.51 ± 0.009 degrees.
- 5 36. The compound of claim 35, having an X-ray diffraction pattern, expressed in terms of 2 theta angles, that includes four or more peaks selected from the group consisting of 16.335, 12.209, 25.156, 27.019, 24.21, 5.255 and 18.511 degrees.
- 10 37. The compound of claim 35, having an X-ray diffraction pattern, expressed in terms of 2 theta angles, that includes peaks of 16.335, 12.209, 25.156, 27.019, 24.21, 5.255 and 18.511 degrees.
38. The compound of claim 35, having substantially the same X-ray diffraction pattern as shown in Figure 2.
- 15 39. A composition comprising ziprasidone as a solid, wherein at least 80 % by weight of said solid ziprasidone is a crystalline form having an X-ray diffraction pattern, expressed in terms of 2 theta angles, that includes four or more peaks selected from the group consisting of 16.34 ± 0.009 , 12.21 ± 0.009 , 25.16 ± 0.009 , 27.02 ± 0.009 , 24.21 ± 0.009 , 5.26 ± 0.009 and 18.51 ± 0.009 degrees.
- 20 40. The composition of claim 39, wherein at least 90 % by weight of said solid ziprasidone is said crystalline form.
41. The composition of claim 39, wherein at least 95 % by weight of said solid ziprasidone is said crystalline form.
- 25 42. The composition of claim 39, wherein at least 99 % by weight of said solid ziprasidone is said crystalline form.
43. A pharmaceutical composition comprising the compound of claim 35 and one or more pharmaceutically acceptable excipients.
44. The pharmaceutical composition of claim 35, wherein said composition is a solid dosage form for oral administration.
- 30 45. The pharmaceutical composition of claim 44, wherein said dosage form is a tablet.
46. A method of treating a psychosis, comprising administering to a patient in need of such treatment an effective amount of the compound of claim 35.
- 35 47. A process for preparation of a crystalline form of ziprasidone, said process comprising:

- 17 -

- a. providing a solution of a salt of ziprasidone in an alcoholic solvent;
- b. treating said solution with an aqueous basic solution thereby forming a precipitate; and

5 c. isolating the precipitate, which is said crystalline form of ziprasidone.

48. The process of claim 47, wherein said salt of ziprasidone is ziprasidone mesylate.

49. The process of claim 48, wherein said ziprasidone mesylate is prepared by 10 a process comprising reacting 6-chloro-5-(2-chloroethyl) oxindole with 3-(1-piperazinyl)-1,2-benzisothiazole.

50. The process of claim 47, wherein said alcoholic solvent is methanol.

51. The process of claim 47, wherein said aqueous basic solution is aqueous caustic lye solution.

52. The process of claim 47, wherein said aqueous basic solution is aqueous sodium hydroxide solution or aqueous potassium hydroxide solution.

53. A pharmaceutical composition comprising the compound of claim 35 and one or more pharmaceutically acceptable excipients.


54. The pharmaceutical composition of claim 53, wherein said composition is a solid dosage form for oral administration.

20 55. The pharmaceutical composition of claim 54, wherein said dosage form is a tablet.

56. A crystalline form of ziprasidone, which is prepared by the process of claim 47.


1/2

FIG. 1



2/2

FIG. 2



INTERNATIONAL SEARCH REPORT

National Application No
PCT/US 03/38489

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D417/12 A61K31/428 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BEILSTEIN Data, EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOWARD H R ET AL: "3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents" JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 1, 5 January 1996 (1996-01-05), pages 143-148, XP000652318 the whole document	1-56
X	US 4 831 031 A (LOWE J A ET AL) 16 May 1989 (1989-05-16) the whole document, particularly column 13, lines 13-17	1-56
X	EP 1 157 726 A (PFIZER PRODUCTS INC.) 28 November 2001 (2001-11-28) the whole document	1-56

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *E* document member of the same patent family

Date of the actual completion of the international search

29 April 2004

Date of mailing of the international search report

07/05/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/38489

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 965 343 A (PFIZER PRODUCTS INC.) 22 December 1999 (1999-12-22) the whole document ---	1-56
X	EP 0 586 191 A (PFIZER INC.) 9 March 1994 (1994-03-09) cited in the application the whole document ---	1-56
X	EP 0 584 903 A (PFIZER INC.) 2 March 1994 (1994-03-02) cited in the application the whole document ---	1-56
X	WO 00/59489 A (SEPRACOR INC.) 12 October 2000 (2000-10-12) example 1 ---	1-56
X	WO 97/42190 A (PFIZER INC.) 13 November 1997 (1997-11-13) example 1 ---	1-56
X	WO 95/00510 A (PFIZER INC.) 5 January 1995 (1995-01-05) example 9 ---	1-56
P, X	WO 03/063833 A (PFIZER PRODUCTS INC.) 7 August 2003 (2003-08-07) the whole document, particularly page 51 lines 15-22 ----	1-56
P, X	WO 03/070246 A (PFIZER PRODUCTS INC.) 28 August 2003 (2003-08-28) example 2 ----	1-56

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/38489

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 16 and 46 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 03/38489

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4831031	A	16-05-1989	US	4883795 A	28-11-1989
EP 1157726	A	28-11-2001	AU BG BR CA CN CZ EA EE EP HR HU ID JP NO NZ PL SG SK TR US ZA	4805601 A 105518 A 0102129 A 2349136 A1 1326803 A 20011726 A3 3261 B1 200100284 A 1157726 A1 20010399 A1 0102179 A2 30368 A 2002028475 A 20012571 A 511966 A 347736 A1 96223 A1 6882001 A3 200101453 A2 2002016498 A1 200104207 A	13-12-2001 31-12-2001 21-05-2002 26-11-2001 19-12-2001 13-02-2002 27-02-2003 15-02-2002 28-11-2001 31-12-2002 28-01-2002 29-11-2001 29-01-2002 27-11-2001 26-11-2002 03-12-2001 23-05-2003 04-04-2002 21-12-2001 07-02-2002 25-11-2002
EP 965343	A	22-12-1999	AT AU AU BG BR CA DE DE DK EA EP ES HR HU ID JP JP JP KR NO NZ PL SG SI SK TR US ZA	240732 T 753820 B2 3398399 A 103489 A 9902268 A 2274338 A1 69908021 D1 69908021 T2 965343 T3 2223 B1 0965343 A2 2197581 T3 990193 A1 9901960 A2 23546 A 3441676 B2 2000007566 A 2002003492 A 2000006143 A 992892 A 336271 A 333737 A1 77243 A1 965343 T1 76999 A3 9901379 A2 6150366 A 9903938 A	15-06-2003 31-10-2002 23-12-1999 31-07-2000 02-05-2000 15-12-1999 26-06-2003 27-11-2003 04-08-2003 28-02-2002 22-12-1999 01-01-2004 29-02-2000 28-08-2000 04-05-2000 02-09-2003 11-01-2000 09-01-2002 25-01-2000 16-12-1999 27-10-2000 20-12-1999 19-12-2000 31-10-2003 11-12-2000 21-01-2000 21-11-2000 14-12-2000
EP 586191	A	09-03-1994	US AU AU BR CA	5312925 A 657231 B2 4600493 A 9303014 A 2095587 A1	17-05-1994 02-03-1995 16-06-1994 15-03-1994 27-02-1994

INTERNATIONAL SEARCH REPORT

International Application No.

US 03/38489

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 586191	A		CA 2105114 A1 CN 1089607 A , B CZ 9301789 A3 DE 9312903 U1 EG 20251 A EP 0586191 A1 FI 933804 A HU 67023 A2 IL 106777 A JP 2742372 B2 JP 6157521 A MX 9305277 A1 NO 933093 A NZ 248543 A PL 300235 A1 PL 174396 B1 RU 2081116 C1 TW 422845 B US 5338846 A ZA 9306394 A	02-03-1994 20-07-1994 13-04-1994 05-01-1994 31-05-1998 09-03-1994 02-03-1994 30-01-1995 15-04-1997 22-04-1998 03-06-1994 31-03-1994 02-03-1994 26-07-1995 05-04-1994 31-07-1998 10-06-1997 21-02-2001 16-08-1994 28-02-1995
EP 584903	A	02-03-1994	US 5206366 A AT 206422 T AU 642836 B1 BR 9302065 A CA 2095587 A1 CN 1083061 A , B CZ 9300877 A3 DE 69330853 D1 DE 69330853 T2 DK 584903 T3 EG 20214 A EP 1029861 A1 EP 0584903 A1 ES 2161703 T3 FI 932012 A HU 65750 A2 IL 105622 A JP 2742370 B2 JP 6184143 A KR 123441 B1 MX 9302813 A1 NO 931656 A NZ 247539 A PL 299002 A1 PT 584903 T RU 2061695 C1 SI 9300287 A SK 48593 A3 US 5338846 A ZA 9306225 A	27-04-1993 15-10-2001 28-10-1993 26-07-1994 27-02-1994 02-03-1994 13-04-1994 08-11-2001 02-05-2002 03-12-2001 30-11-1997 23-08-2000 02-03-1994 16-12-2001 27-02-1994 28-07-1994 15-06-1998 22-04-1998 05-07-1994 24-11-1997 28-02-1994 28-02-1994 26-09-1995 21-03-1994 28-02-2002 10-06-1996 31-03-1994 06-04-1994 16-08-1994 27-02-1995
WO 0059489	A	12-10-2000	AU 4062900 A CA 2363942 A1 EP 1165083 A2 JP 2002541098 T WO 0059489 A2	23-10-2000 12-10-2000 02-01-2002 03-12-2002 12-10-2000

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 03/38489

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
WO 9742190	A	13-11-1997	AP 838 A AT 236902 T AU 730856 B2 AU 1936897 A BG 63601 B1 BG 102893 A BR 9708932 A CA 2252895 A1 CN 1216990 A , B CZ 9803494 A3 DE 69720719 D1 DE 69720719 T2 DK 904273 T3 EA 1180 B1 EP 0904273 A1 ES 2192264 T3 HK 1017893 A1 HR 970235 A1 HU 9902808 A2 WO 9742190 A1 ID 17504 A IL 126590 A JP 3102896 B2 JP 11509865 T KR 2000010822 A NO 985193 A NZ 508303 A PL 329880 A1 PT 904273 T SI 904273 T1 SK 150598 A3 TR 9802241 T2 TW 427989 B US 6110918 A ZA 9703875 A		03-05-2000 15-04-2003 15-03-2001 26-11-1997 28-06-2002 30-09-1999 03-08-1999 13-11-1997 19-05-1999 15-09-1999 15-05-2003 06-11-2003 07-07-2003 30-10-2000 31-03-1999 01-10-2003 07-03-2003 30-06-1998 28-03-2000 13-11-1997 08-01-1998 25-11-2001 23-10-2000 31-08-1999 25-02-2000 06-11-1998 27-07-2001 12-04-1999 30-06-2003 31-08-2003 13-03-2000 22-02-1999 01-04-2001 29-08-2000 06-11-1998	
WO 9500510	A	05-01-1995	US 5359068 A CA 2166203 A1 EP 0706524 A1 FI 956279 A WO 9500510 A1 JP 2667987 B2 JP 8506354 T		25-10-1994 05-01-1995 17-04-1996 27-12-1995 05-01-1995 27-10-1997 09-07-1996	
WO 03063833	A	07-08-2003	WO 03063833 A1 US 2003228358 A1		07-08-2003 11-12-2003	
WO 03070246	A	28-08-2003	WO 03070246 A1 US 2004048876 A1		28-08-2003 11-03-2004	